Current and future options in cholesterol lowering treatments

Research output: Contribution to journalReview articlepeer-review

Abstract

The relative risk reduction of cardiovascular events is proportional to the absolute reduction in LDL-C levels, the primary target of therapy, no matter the way of reduction. During the last decades, the therapeutic regimens for reducing the LDL-C levels have been immerged and improved, with favorable effects on the atherosclerotic process and clinical benefits of various cardiovascular outcomes. From a practical view of point, this review is focusing only on the current available lipid lowering agents: statins, ezetimibe, anti PCSK9 monoclonal antibodies, the small interfering RNA (siRNA) agent, Inclisiran, and Bempedoic acid. The recent changes in lipid lowering regimens, including the early combination of lipid lowering agents and “Low LDL-C” levels <30 mg/dL for high/very high cardiovascular risk patients will also be discussed.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalEuropean Journal of Internal Medicine
Volume112
DOIs
StatePublished - Jun 2023

Keywords

  • Anti PCSK9 monoclonal antibodies
  • Bempedoic acid
  • Ezetimibe
  • Inclisiran
  • Lipid lowering agents
  • Statins

Fingerprint

Dive into the research topics of 'Current and future options in cholesterol lowering treatments'. Together they form a unique fingerprint.

Cite this